Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

• Status: Active, not recruiting
• Trial end date: 2022-09-01

Summary

The objective of the trial is to assess the efficacy of Durvalumab and Tremelimumab in comparison to doxorubicin in treatment-naïve Soft tissue sarcoma patients

• Phase: Phase 2

Details

• Lead Sponsor: AIO-Studien-gGmbH
• Collaborator: AstraZeneca
• Treatments: Antibodies, Monoclonal; Doxorubicin; Durvalumab; Liposomal doxorubicin; Tremelimumab